For individuals considering GLP-1 treatment, the most appropriate next step is a doctor-led consultation rather than self-selecting a specific medication
Tirzepatide typically produces greater weight loss in clinical trials than semaglutide, with patients losing 20-22% body weight versus 15-17% respectively
Our cGMP facilities support both small-molecule and peptide-based metabolic programs
All doses of tirzepatide and semaglutide increased the risk for gastrointestinal adverse events versus placebo, with tirzepatide 15 mg yielding the highest risk for nausea (risk ratio [RR], 3.57), vomiting (RR, 4.35), and diarrhea (RR, 2.04)
If you dont have insurance coverage for provider visits and lab visits, our clinic can help you understand the out-of-pocket costs before proceeding with the program